Long-Term Data from the ABCSG-12 Trial of Adjuvant Zoledronic Acid and Endocrine Therapy


Long-Term Data from the ABCSG-12 Trial of Adjuvant Zoledronic Acid and Endocrine Therapy
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Gnant M et al. The carry-over effect of adjuvant zoledronic acid: Comparison of 48- and 62-month analyses of ABCSG-12 suggests that the benefits of combining zoledronic acid with adjuvant endocrine therapy persist long after completion of therapy. San Antonio Breast Cancer Symposium 2010;Abstract P5-11-02.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.